✦ LIBER ✦

Cross-reactive antiidiotypic antibodies against human rheumatoid factors from patients with juvenile rheumatoid arthritis

✍ Scribed by Terry L. Moore; Thomas G. Osborn; Robert W. Dorner

Publisher: John Wiley and Sons
Year: 1989
Tongue: English
Weight: 668 KB
Volume: 32
Category: Article
ISSN: 0004-3591
DOI: 10.1002/anr.1780320607

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Suppression of rheumatoid factor synthes

Suppression of rheumatoid factor synthesis by antiidiotypic antibody in rheumatoid arthritis patients with cross-reactive idiotypes

✍ Tsutomu Takeuchi; Osamu Hosono; Jun Koide; Mitsuo Homma; Tohru Abe 📂 Article 📅 1985 🏛 John Wiley and Sons 🌐 English ⚖ 813 KB

Demonstration of a cross-reactive idioty

Demonstration of a cross-reactive idiotype (idrq) in rheumatoid factors from patients with rheumatoid arthritis but not in rheumatoid factors from healthy, Aged subjects

✍ Alejandro Ruiz-Arguelles; Miguel Presno-Bernal 📂 Article 📅 1989 🏛 John Wiley and Sons 🌐 English ⚖ 483 KB 👁 2 views

Rheumatoid factors from patients with rh

Rheumatoid factors from patients with rheumatoid arthritis react with tryptophan 60 and 95, lysine 58, and arginine 97, on human β2-microglobulin

✍ Ralph C. Williams Jr; Christine C. Malone; John B. Harley 📂 Article 📅 1993 🏛 John Wiley and Sons 🌐 English ⚖ 1022 KB

To define precise epitopes on human P2-microglobulin (P2m) reacting with polyclonal IgM rheumatoid factors (RF) from patients with rheumatoid arthritis (RA). Methods. Ten polyclonal RF were tested for their human P2m epitop+binding specificities using the entire 99-amino acid sequence synthesized a

Antibodies against A peptide sequence lo

Antibodies against A peptide sequence located in the linker region of the HMG-1/2 box domains in sera from patients with juvenile rheumatoid arthritis

✍ Frank Jung; Gunter Neuer; Friedlinde A. Bautz 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 622 KB

Radiographic, clinical, and functional o

Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti–tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo-controlled, 52-week trial

✍ Edward C. Keystone; Arthur F. Kavanaugh; John T. Sharp; Hyman Tannenbaum; Ye Hua 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 167 KB 👁 2 views

Golimumab, a human anti–tumor necrosis f

Golimumab, a human anti–tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four–week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis

✍ Paul Emery; Roy M. Fleischmann; Larry W. Moreland; Elizabeth C. Hsia; Ingrid Str 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 135 KB 👁 1 views